Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphoma
Phase 2
- Conditions
- Follicular lymphoma
- Registration Number
- JPRN-UMIN000007950
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Entry completed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with uncontrollable infection. 2) Intolerable allergy for rituximab or drugs derived from murine proteins. 3) Previous history of allogeneic stem cell transplant. 4) Pregnant (or possibly pregnant) patient 5) Patients receiving anti-coagulants or anti-thrombotic agents. 6) Patients with hemorrhagic symptoms. 7) Patients receiving external radiation for more than 25% of total bone marrow. 8) Patients planning to undergo rituximab maintenance therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method